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FAK regulates IL‑33 expression 
by controlling chromatin 
accessibility at c‑Jun motifs
Billie G. C. Griffith1,6, Rosanna Upstill‑Goddard2,6, Holly Brunton2,3, Graeme R. Grimes4, 
Andrew V. Biankin2, Bryan Serrels2,5*, Adam Byron1* & Margaret C. Frame1*
Focal adhesion kinase (FAK) localizes to focal adhesions and is overexpressed in many cancers. FAK 
can also translocate to the nucleus, where it binds to, and regulates, several transcription factors, 
including MBD2, p53 and IL‑33, to control gene expression by unknown mechanisms. We have 
used ATAC‑seq to reveal that FAK controls chromatin accessibility at a subset of regulated genes. 
Integration of ATAC‑seq and RNA‑seq data showed that FAK‑dependent chromatin accessibility is 
linked to differential gene expression, including of the FAK‑regulated cytokine and transcriptional 
regulator interleukin‑33 (Il33), which controls anti‑tumor immunity. Analysis of the accessibility peaks 
on the Il33 gene promoter/enhancer regions revealed sequences for several transcription factors, 
including ETS and AP‑1 motifs, and we show that c‑Jun, a component of AP‑1, regulates Il33 gene 
expression by binding to its enhancer in a FAK kinase‑dependent manner. This work provides the 
first demonstration that FAK controls transcription via chromatin accessibility, identifying a novel 
mechanism by which nuclear FAK regulates biologically important gene expression.
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that is overexpressed in many cancers, including 
squamous cell carcinoma (SCC)1, breast,  colorectal2 and pancreatic  cancer3. In addition to well-known localiza-
tion at integrin-mediated cell–matrix adhesion sites (focal adhesions), FAK can localize to the nucleus, where it 
binds a number of transcription factors, including  p534,  Gata45 and  Runx16, to regulate the expression of Cdkn1a 
(which encodes p21), Vcam1 and Igfbp3, respectively. By binding to these transcription factors, FAK has been 
linked to cancer-associated processes such as  inflammation5,  proliferation6 and  survival4.
Our previous work demonstrated that, in mutant H-Ras-driven murine SCC cells, nuclear FAK controls 
expression of cytokines and chemokines, for example Ccl5, to drive recruitment of regulatory T cells into the 
tumor microenvironment, resulting in suppression of the antitumor  CD8+ T cell response and escape from anti-
tumor  immunity7. FAK regulates biologically important chemokines via its kinase activity and adaptor functions 
in the nucleus; briefly, nuclear FAK interacts with many transcription factors and accessory proteins in a gene 
expression-regulatory  network7. Crucially, this includes the pro-inflammatory cytokine IL-33 that can either 
be found in the nucleus or be released from cells that are damaged or dying (alarmin)8. In SCC cells however, 
IL-33 is not secreted, but instead is translocated to the nucleus and functions there; in turn, nuclear IL-33 drives 
expression of immunosuppressive chemokines, such as Ccl5 and Cxcl10, and we showed that IL-33 functions 
exclusively downstream of FAK in promoting pro-inflammatory gene expression and tumor  growth9. However, 
the mechanisms by which FAK activity controls Il33 gene expression are not understood, and this important 
extension of previous work is investigated here.
Our previous findings have suggested that FAK is present in the chromatin fraction and interacts with chro-
matin modifiers in the  nucleus7. Therefore, we wanted to investigate whether FAK controls genome-wide chroma-
tin accessibility changes and if these chromatin changes contribute to FAK-dependent gene expression, which to 
our knowledge has never been explored. To understand potential molecular mechanisms by which FAK regulates 
expression of genes like Il33, we examined FAK-dependent chromatin accessibility changes and transcription 
factor motif enrichment across the genome using ATAC-seq and integrated those data with RNA-seq. This 
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revealed that FAK regulates chromatin accessibility of a subset of genes, and a number of these were differentially 
expressed in a FAK- and FAK kinase-dependent manner, including the previously identified FAK downstream 
effector Il33. Motif-enrichment analysis indicated that there was enrichment of sequence motifs known to bind 
ETS and c-Jun/AP-1 transcription factor family members on the Il33 promoter and enhancer regions which are 
affected by FAK. Validation experiments confirmed that c-Jun is a key regulator of IL-33 expression in SCC cells 
by binding to the Il33 enhancer, and that FAK’s kinase activity is important for regulating chromatin accessibility 
at this site. Analysis of genome-wide motif enrichment indicated that FAK likely regulates many more transcrip-
tion factors beyond those already reported. Taken together, our data suggest that FAK is a common regulator 
of gene expression via modulating transcription factor binding to biologically relevant target gene promoters/
enhancers by controlling chromatin accessibility, such as we demonstrate here using Il33 as an exemplar. In 
turn, FAK-dependent gene expression changes, including Il33, are critically associated with cancer-associated 
 phenotypes7,9. This is the first demonstration of how nuclear FAK can contribute to gene expression, and we 
report a new activity in the nucleus for a classical adhesion protein.
Results
FAK regulates transcription factor motif accessibility across the genome. FAK does not contain 
a DNA binding sequence and therefore likely regulates transcription indirectly, potentially through interactions 
with transcription factors and co-factors. To identify which transcription factors may be candidate mediators of 
FAK-dependent gene expression, we used ATAC-seq to analyze active (accessible) chromatin in FAK-deficient 
SCC cells or cells expressing different FAK mutant proteins. Specifically, we compared SCC cells in which FAK 
had been depleted by Cre-lox-mediated Ptk2 (which encodes FAK) gene deletion (FAK−/− cells) with the same 
cells re-expressing wild-type FAK (FAK-WT-expressing cells) or FAK mutants that were impaired in nuclear 
localization (FAK-nls-expressing cells) or deficient in kinase activity (FAK-kd-expressing cells) (cell lines gener-
ated  previously7,10). These permitted the identification of FAK-dependent, FAK nuclear localization-dependent 
and FAK kinase-dependent alterations in chromatin accessibility and transcription factor motif enrichment in 
accessible regions of chromatin across the genome.
Chromatin accessibility analysis of ATAC-seq data detected 20,000–60,000 peaks (accessible regions) per 
sample (Supplementary Fig. S1A; see Supplementary Table S1 for further details of ATAC-seq statistics). The 
standard peak number in ATAC-seq experiments can vary depending on cell type, species, context and variations 
in the ATAC-seq protocol. Importantly, the peak number reported in our study is in the medium-to-high range 
for an ATAC-seq experiment performed in mouse cells (see additional file 2  in11).
The majority of peaks in FAK-WT-, FAK-nls-, FAK-kd-expressing as well as FAK−/− cell lines were located 
0–100 kb from the transcriptional start sites (TSS) (Supplementary Fig. S1B). The distance of ATAC-seq peaks 
from the TSS suggests that the accessible regions were predominantly located in likely  enhancer12 and  promoter13 
regions.
We identified differentially accessible gene regions using the DiffBind  package14. Differential peak calling 
was performed for each pairwise comparison for which FAK-WT samples were compared with each of the FAK 
knockout (FAK−/−) and FAK mutant (FAK-nls- and FAK-kd-expressing) cell lines. From this analysis, it was 
apparent that a subset of genes are regulated by FAK-dependent changes in chromatin accessibility (discussed 
further below).
We next analyzed the transcription factor motif sequences present in FAK-dependent differentially accessible 
peaks (hereafter termed motif-enrichment analysis). Motif-enrichment analysis allowed us to predict which tran-
scription factors were regulating genes across the genome by analyzing the motif sequences in ATAC-seq peaks. 
We used the HOMER  tool15 to identify motif binding sites (i.e. genomic regions that match known transcription 
factor motifs) in the differentially accessible peaks identified by DiffBind analysis. Motifs in FAK-WT-enriched 
peaks were statistically compared to all the motifs identified in peaks called in the FAK-nls-, FAK-kd-expressing 
or FAK−/− cells. This was expressed as a proportion of target sequences containing that motif (motifs in peaks 
enriched in FAK-WT-expressing cells) compared to the proportion of background sequences containing that 
motif (all motifs identified in the respective comparison, i.e. FAK-nls-, FAK-kd-expressing or FAK−/− cells). 
This analysis detected multiple statistically significant changes in motif enrichment in differentially accessible 
peaks from FAK-WT vs FAK-deficient (FAK−/−) SCC cells (196 transcription factor motifs), FAK-WT- vs FAK-
kd-expressing SCC cells (118 transcription factor motifs) and FAK-WT vs FAK-nls-expressing SCC cells (205 
transcription factor motifs) (Benjamini–Hochberg-corrected P ≤ 0.05) (Supplementary Data S1). Importantly, 
the number of motifs identified in the ATAC-seq peaks were similar to those in previous published ATAC-seq 
datasets (see supplementary file 9  in16). These findings suggest that FAK regulates transcription factor motif 
enrichment in accessible regions of chromatin across the SCC genome.
In the motif-enrichment analyses of FAK-WT-expressing cells vs FAK−/− cells and FAK-WT- vs FAK-nls-
expressing cells, the two most highly enriched transcription factor motifs were for Jun-AP-1 and Fosl2 (all 
Benjamini–Hochberg-corrected P = 0), which exhibited an almost two-fold enrichment in motifs in the target 
(% target, FAK-WT-expressing cells) compared to the motifs identified in the background (% background, 
FAK−/− cells or FAK-nls-expressing cells) (Fig. 1A). The top two hits in the motif-enrichment analysis of FAK-
WT- vs FAK-kd-expressing cells were motifs for Ets1 and Etv1 (all Benjamini–Hochberg-corrected P = 0), which 
likewise revealed a two-fold enrichment in these motifs in the target (% target, FAK-WT-expressing cells) com-
pared to the background motifs (% background, FAK-kd-expressing cells) (Fig. 1A). These data imply that FAK 
and specific FAK functions (kinase activity and nuclear localization) robustly regulate enrichment of particular 
AP-1 and ETS motifs within accessible chromatin regions in SCC cells.
We used set analysis to identify FAK-dependent transcription factors motif sequences in the ATAC-seq 
peaks (Supplementary Data S1). This analysis revealed enrichment of transcription factor motifs controlled by 
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Figure 1.  FAK regulates AP-1 and ETS motifs in accessible regions of chromatin. (A) The top two transcription 
factor motifs enriched in the FAK-WT-expressing vs FAK−/− SCC cells (upper panel), FAK-WT- vs FAK-nls-
expressing SCC cells (middle panel) and FAK-WT- vs FAK-kd-expressing SCC cells (lower panel) motif-
enrichment analyses. Motifs in FAK-WT-enriched peaks (% target) were compared to all the motifs identified in 
peaks called in either the FAK-nls-expressing cells, FAK-kd-expressing cells or FAK−/− cells (% background). The 
name of the transcription factor motifs are reported next to the consensus sequence (images from  HOMER15 
published under a CC BY open access license), followed by the proportion of target sequences with that motif 
(% target) and the proportion of background sequences with that motif (% background). P ≤ 1 × 10−31 and 
q = 0 for all motifs shown. (B) Motif-enrichment data for FAK-WT-expressing cells vs FAK−/− cells, FAK-
nls-expressing cells or FAK-kd-expressing cells were filtered by set analysis to identify transcription factors 
enriched in FAK-WT-expressing cells but not enriched in FAK−/−, FAK-nls and FAK-kd motif-enrichment 
analyses (intersection set, red circle). (C) Protein domain-enrichment analysis of transcription factors associated 
with motifs that are enriched in FAK-WT-expressing cells. The full FAK-WT-expressing cells vs FAK−/− cells 
motif-enrichment analysis (transcription factors predicted from both significant and non-significant motifs) 
was used as the background list. All terms with Benjamini–Hochberg-corrected P ≤ 0.05 are displayed 
(− log10-transformed corrected P-values are shown). The full domain name is reported in parentheses next to 
the corresponding SMART domain term. (D) Transcription factors that have enriched motifs in FAK-WT-
expressing cells (intersection set in B, red circle) were used to construct a functional association network using 
Ingenuity Pathway Analysis. Only direct, mammalian interactions are shown. Edge (line) style represents type 
of physical or functional connection. Node (circle) size indicates the connectivity of the node (number of 
associations that node has within the network). Node borders for transcription factors from the AP-1 family are 
red and for the ETS transcription factors are purple. The network was structured using the yFiles hierarchical 
layout algorithm. n = 2 biological replicates.
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specific FAK functions (scaffolding, nuclear-localization and kinase activity). For example, in the FAK-WT vs 
FAK−/− motif-enrichment analysis, there was enrichment of motifs known to primarily bind p53, which were 
not enriched in the FAK-WT vs FAK-nls or FAK-WT vs FAK-kd analyses (Supplementary Data S1), suggest-
ing that FAK scaffolding functions may regulate exposure of p53 binding motifs. To establish the most relevant 
transcription factors responsible for FAK-WT-dependent gene expression, we filtered the transcription factors 
known to bind to FAK-regulated motifs that were only enriched in the FAK-WT-expressing cells when compared 
to FAK−/− cells, FAK-nls-expressing cells and FAK-kd-expressing cells (63 transcription factor motifs; Fig. 1B 
and worksheet 4 in Supplementary Data S1).
To identify which transcription factors may regulate gene expression in the FAK-WT-expressing cells, we 
performed protein domain-enrichment analysis on the set of transcription factors known to bind FAK-regulated 
motifs (Fig. 1C). This analysis indicated that there was an over-representation of transcription factors known 
to bind motifs containing ETS (term SM00413:ETS, Benjamini–Hochberg-corrected P = 1.02 × 10−10) and PNT 
domains (term SM00251:SAM_PNT, Benjamini–Hochberg-corrected P = 1.06 × 10−5; Fig. 1C), including the ETS 
transcription factor family members Fli1, Elf3, Elf5, Gabpa, Spdef, Erg, Ehf and Ets1. Furthermore, there was also 
an enrichment for transcription factors known to bind motifs that contain basic-leucine zipper domains (term 
SM00338:BRLZ, Benjamini–Hochberg-corrected P = 0.0033; Fig. 1C), including members of the AP-1 family, 
such as c-Jun, JunB, Fosl1, Fosl2 and Atf3. Thus, our analyses revealed FAK-dependent enrichment of a set of 
sequence motifs known to bind AP-1 and ETS transcription factors.
To understand better the likely transcription factors responsible for FAK-dependent gene expression, we per-
formed interactome analysis to determine putative connections between transcription factors known to associate 
with FAK-regulated motifs. We reasoned that transcription factors with exposed motifs in FAK-WT-expressing 
cells that have a large number of functional associations with other predicted transcription factors are more likely 
to be important mediators of FAK-dependent transcription. We constructed a functional association network, 
incorporating curated protein–protein and protein-DNA interactions, of the transcription factors whose motifs 
were enriched in FAK-WT-expressing cells (Fig. 1D). The network analysis revealed that transcription factors 
known to bind FAK-regulated motifs have a large number of connections with other transcription factors known 
to bind FAK-regulated motifs (Fig. 1D). The most highly connected transcription factor was the AP-1 member 
c-Jun (outlined in red in Fig. 1D), and network topology implied that c-Jun is a key signal integrator between 
all the other transcription factors in the network. Other well-connected nodes in the network were members of 
the AP-1 family, including JunB, Atf3 and Fosl1 (outlined in red in Fig. 1D). In addition, certain members of the 
ETS transcription factor family had many physical and functional connections within the network, namely Ets1 
and Spi1 (outlined in purple in Fig. 1D). Collectively, these data suggest that FAK regulates motif enrichment 
in accessible regions of chromatin, in particular sequences known to bind to the AP-1 and ETS transcription 
factor family members.
FAK regulates chromatin accessibility at a subset of genes, including Il33. Differential peak-call-
ing analysis identified chromatin accessibility changes that were dependent on FAK, as well as FAK kinase activ-
ity and its nuclear localization (Fig. 2A). All ATAC-seq peaks were set to 500 bp to allow comparison between 
peaks in the SCC cell lines used in this study, and we reported distances from the ATAC-seq peak center as a 
heatmap (red indicates high read count (highly accessible region) in Fig. 2A). This analysis revealed ATAC-seq 
peaks across the genome with differential accessibility (varied read count) when comparing FAK-WT SCC cells 
to FAK−/−, FAK-nls-expressing and FAK-kd-expressing SCC cells, identifying changes in a subset of genes that 
varied depending on FAK status (Fig. 2A). These data implied that FAK regulates the chromatin accessibility at 
a subset of genes.
We next identified which genes were regulated by FAK-dependent changes in chromatin accessibility using 
comparisons between the cell lines that varied only in FAK status. We wanted to determine which genes were 
associated with the ATAC-seq peaks enriched in FAK-WT-expressing cells (as identified by differential peak call-
ing) to understand which genes are regulated by FAK-dependent accessibility changes. To assign each ATAC-seq 
peak to genes, we used  ChIPseeker17, which links each peak to the closest TSS using data from the University of 
California, Santa Cruz, genome browser annotation database (https ://genom e.ucsc.edu/). We used FAK RNA-seq 
data to confirm whether the genes that were regulated by FAK-dependent changes in chromatin accessibility were 
also differentially expressed in a FAK- and FAK kinase-dependent manner (Fig. 2B and FAK RNA-seq dataset 
reported in Supplementary Data S2). Set analysis identified genes that were either up- or down-regulated in a 
FAK- or FAK kinase-dependent manner, and also those genes whose FAK-dependent changes were associated 
with chromatin accessibility changes (intersection sets in upper panels in Fig. 2B). We found 36 genes whose 
expression and chromatin accessibility profiles were both regulated by FAK and its kinase activity (intersection 
sets in lower panel in Fig. 2B). Comparison of the FAK-nls mutant chromatin accessibility data to this subset 
of genes revealed that most of these are also dependent on FAK’s ability to localize to the nucleus (asterisks in 
lower panel in Fig. 2B).
As an exemplar, we next focused on one of these genes, Il33, because we had previously reported it as a 
FAK-regulated cytokine of biological significance in mediating FAK-dependent anti-tumor  immunity9. Using 
ATAC-seq data to investigate whether chromatin accessibility was one mechanism by which FAK regulates Il33, 
we found that there were ATAC-seq peaks in FAK-WT-expressing SCC cells on Il33 enhancer (− 3199 from 
TSS) and promoter (+ 821 from TSS) regions (Fig. 2C). Moreover, these peaks were absent in the FAK-kd- and 
FAK-nls-expressing cells and reduced in FAK−/− cells, which had no detectable peak on the promoter region and 
a suppressed ATAC-seq peak on the enhancer region. However, we note that the suppressed ATAC-seq peak on 
one replicate of the FAK−/− cells (FAK−/−2) did not have sufficient read count to be identified as an ATAC-seq 
peak, and therefore the peak was not called. We conclude that FAK regulates chromatin accessibility at a subset 
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Figure 2.  FAK regulates chromatin accessibility of a subset of genes, including the cytokine and transcriptional 
regulator Il33. (A) Heatmap representation of chromatin accessibility changes between FAK-WT, FAK−/−, FAK-
nls and FAK-kd SCC cells (all peaks displaying differential accessibility are shown). Highly accessible regions 
(high read count, peak center) are shown in red, whereas less accessible regions (low read count) are indicated 
in blue. The y-axis of the heatmap reports the distance from the ATAC-seq peak center. Significantly different 
peaks were defined as those with a false discovery rate (FDR) ≤ 0.05. (B) The upper panel shows overlap of 
FAK-dependent (left) or FAK kinase-dependent (right) chromatin accessibility data with FAK-WT vs FAK−/− 
or FAK-WT vs FAK-kd SCC RNA-seq differential expression data, respectively. Genes that were upregulated 
according to RNA-seq data were compared with genes exhibiting enhanced chromatin accessibility and vice 
versa. The lower panel (gray box) shows set analysis of common downregulated genes (left) and common 
upregulated genes (right) present in FAK−/− and FAK-kd cells (with respect to FAK-WT cells), which also show 
changes in chromatin accessibility identified to be in common between FAK-WT vs FAK−/− and FAK-WT vs 
FAK-kd analyses. In the lower panel, genes that display chromatin accessibility changes in FAK-nls cells in 
addition to FAK−/− and FAK-kd cells are indicated by an asterisk. RNA-seq data for FAK-WT-expressing vs 
FAK−/− SCC cells were reported  previously38 and re-analyzed here alongside the data for FAK-WT- vs FAK-kd-
expressing cells. (C) Chromatin accessibility traces from FAK-WT, FAK−/−, FAK-nls and FAK-kd SCC ATAC-
seq samples. Genomic regions that display FAK-dependent changes in chromatin accessibility upstream of 
the Il33 gene are outlined in pink (enhancer) and blue (promoter region). Coverage is indicated on the y-axis, 
whereas genomic distance is shown on the x-axis. Below the chromatin accessibility traces is a schematic of the 
location of the Il33 gene with respect to the ATAC-seq peaks. In (A) and (C), numbers appended to sample 
names indicate the biological replicate number for the respective cell line. n = 2 biological replicates for the 
ATAC-seq dataset (A–C); n = 3 biological replicates for the RNA-seq dataset (B).
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of gene promoters, and some of these are differentially expressed in a FAK-dependent manner, as exemplified 
by Il33. This suggests that FAK-regulated, biologically important gene expression alterations may be controlled 
by FAK-dependent chromatin accessibility changes.
FAK regulates IL‑33 expression via chromatin accessibility at the c‑Jun motif in the Il33 
enhancer. In order to define key transcription factors that drive FAK-dependent Il33 expression in mouse 
SCC cells, we performed motif-enrichment analysis on the ATAC-seq peaks proximal to the Il33 promoter 
and enhancer regions in FAK-WT-expressing cells using HOMER (using data depicted in Fig. 2C). Analysis 
of the raw peak-calling data revealed that there was a number of peaks upstream of the Il33 gene in the FAK-
WT-expressing cells as well as FAK−/− cells, FAK-nls- and FAK-kd-expressing SCC cell lines between − 7480 
and − 42,315 bp upstream of the TSS. To create a refined list to identify the key transcription factors important 
for Il33 expression in FAK-WT-expressing cells, we excluded all the transcription factor motifs that were present 
in the aforementioned peaks upstream of the Il33 gene in FAK−/− cells, FAK-nls- and FAK-kd-expressing cells 
from our list of putative Il33 transcription factor motifs. This identified 24 FAK-dependent transcription factor 
motifs, including sequence motifs known to be bound by the AP-1 components c-Jun, Atf2 and Atf7 (Fig. 3A 
and Supplementary Data S3).
It is well established that in order for a transcriptional event to occur, transcription factors often need to 
form complexes with other transcription factors in the same or different families. For example, it is well known 
that c-Jun homodimerizes, as well as heterodimerizes with c-Fos and Fra or Atf family members, to regulate 
the expression of AP-1-dependent  genes18. Furthermore, the transcription factor Nr4a1 has been shown to bind 
and co-operate with c-Jun to regulate the transcription of the Star  gene19. Therefore, we addressed whether 
the transcription factors predicted to regulate Il33 expression in FAK-WT-expressing cells can bind to and/or 
regulate each other. We reasoned that highly connected transcription factors may represent key nodes in the Il33 
transcription factor network and, therefore, potentially important regulators of IL-33 expression. Generation 
of an Il33 transcription factor regulatory network for FAK-WT-expressing cells indicated that the transcription 
factors known to bind FAK-regulated motifs at the Il33 gene have multiple functional connections (Fig. 3B). 
Indeed, the most highly connected transcription factor was the AP-1 member c-Jun (largest node in Fig. 3B), 
suggesting it may be a key node in the FAK-dependent Il33 transcription factor network.
We next examined nuclear FAK binding partners (described previously  in7) and used interactome analysis 
to contextualize these with regard to transcription factors that may bind to the identified sequence motifs in the 
Il33 gene where accessibility is FAK-regulated. This enabled the prediction of putative Il33 transcription factors 
that have functional connections with nuclear FAK binders and thereby may be regulated by FAK in a direct 
manner (Fig. 3C). The resulting network indicated that the transcription factors with motif sequences on the 
Il33 promoter/enhancer have varying numbers of functional associations with putative nuclear FAK-interactors 
(indicated by node size in Fig. 3C). The transcription factors with the most links to nuclear FAK binding proteins 
were c-Jun and Nr4a1 (Fig. 3C). This implied that there were likely interesting connections between FAK and 
the transcription factors known to access motifs in the Il33 promoter in a FAK-dependent manner. Our net-
work analysis suggested that c-Jun interacts with a number of FAK binders identified  previously7, such as Pin1, 
which has been shown to bind to c-Jun and increase its transcriptional  activity20. The FAK binding partner and 
transcription factor Sp-19 has been reported to bind both the two most highly connected nodes in the network, 
c-Jun (21; left in Fig. 3D) and Nr4a1 (22; right in Fig. 3D). Other nodes that had connections with validated FAK 
binders included Tbp, which binds to the FAK binding protein Taf9 (7; Supplementary Fig. S2) to form the TFIID 
component of the basal transcription factor  complex23. Therefore, our interactome analysis indicates that FAK 
is functionally well connected to transcription factors known to bind to sequence motifs on the Il33 enhancer 
whose accessibility is FAK-regulated.
c‑Jun regulates IL‑33 expression by binding to Il33 enhancer regions. Our nuclear FAK interac-
tome analysis showed that c-Jun was a hub (i.e. a highly connected node) in the Il33 transcription factor network 
(Fig. 3C). c-Jun is a component of the AP-1 family of transcription factors, and it is an important regulator of 
skin  inflammation24. For example, c-Jun proteins are known to be important for the expression of the cytokine 
 CCL525, which we have shown to be regulated by FAK and IL-33, and loss of Jun proteins can lead to the onset of 
a chronic psoriasis-like  disease26. Therefore, we hypothesized that c-Jun may be a likely regulator of inflamma-
tory gene expression in SCC cells (which originate from skin keratinocytes) used in our studies. We performed 
siRNA-mediated depletion of Jun mRNA (which encodes c-Jun) (Fig. 4A), which led to a parallel significant 
downregulation of Il33 mRNA (Fig. 4B) and reduced IL-33 protein expression (Fig. 4C). In addition, the FAK 
and IL-33 target gene in SCC cells, Cxcl10, also showed reduced mRNA levels as a result of Jun knockdown 
(Fig. 4D). Taken together, these data imply that c-Jun is likely an important regulator of IL-33 expression and of 
FAK- and IL-33-dependent target genes.
Next, we performed chromatin immunoprecipitation (ChIP)-qPCR analysis to confirm that c-Jun binds to 
the predicted c-Jun sequence-binding motif at the Il33 enhancer, and whether or not FAK-dependent chromatin 
accessibility changes on the Il33 enhancer are linked to perturbed c-Jun binding. Our  HOMER15 analysis iden-
tified a cAMP response element (CRE) (5′-TGA CGT CA-3′) within the Il33 enhancer peak, which are known 
to bind c-Jun–Atf dimeric  complexes18. We therefore used ChIP to show that c-Jun binds to the CRE motifs 
at the Il33 enhancer in a FAK-dependent manner via accessibility. Primers were designed around the region 
containing the CRE sequence motif in the Il33 enhancer and an unrelated region upstream of this site to control 
for background binding (depicted in Fig. 4E). We used an anti-c-Jun ChIP-grade antibody to pull down DNA 
in formaldehyde-crosslinked, sonicated chromatin preparations from FAK-WT- and FAK-kd-expressing cells, 
since loss of FAK’s kinase activity displayed the most striking loss of chromatin accessibility at the Il33 enhancer 
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Figure 3.  Interactome analysis identifies c-Jun as a key node in the Il33 transcription factor network. (A) Set 
of transcription factors predicted to regulate Il33 expression in FAK-WT SCC cells. Transcription factors that 
regulate Il33 expression were predicted by analyzing transcription factor motif sequences in the ATAC-seq 
promoter and enhancer peaks upstream of the Il33 gene in FAK-WT-expressing cells using  HOMER15. The 
potential Il33 regulators and the respective location of the transcription factor motif upstream of the Il33 gene 
(enhancer or promoter) are listed. (B) Functional association network of the predicted FAK-WT-enriched 
transcription factors on the Il33 gene enhancer/promoter regions. Direct, mammalian connections are shown 
between the predicted transcription factors in FAK-WT-expressing cells. Node borders of predicted enhancer-
associated transcription factors are pink; those predicted to bind the Il33 promoter are blue. Node size indicates 
the connectivity of the node (number of functional connections that protein has within the network). The 
yFiles tree layout algorithm was applied to the network. (C,D) A previously published nuclear FAK interactome 
 dataset7 was integrated with the predicted transcription factors on the Il33 promoter/enhancer regions. 
Upstream, mammalian interactions between the FAK nuclear interactors and the Il33 transcription factors in 
FAK-WT-expressing cells were used to construct the network (C). The two most connected nodes, centered 
around c-Jun (left panel) and Nr4a1 (right panel) are detailed in D. Nodes for transcription factors predicted 
to bind to the Il33 promoter/enhancer regions in FAK-WT-expressing SCC cell lines are colored in yellow; all 
potential FAK interactors that bind to predicted Il33 motifs are colored purple (node labels omitted in C for 
clarity). Red node borders indicate proteins identified as FAK interactors by previous validation  experiments7,9. 
Node size indicates the connectivity of the node. The yFiles organic layout algorithm was applied to the network. 
n = 2 biological replicates for the ATAC-seq dataset (B–D); n = 3 biological replicates for the proteomics dataset 
(C,D).
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(Fig. 2C). Following immunoprecipitation, the DNA was purified and a qPCR was performed, whereby the 
Il33 enhancer region and an upstream background region were amplified. We used the % input method to 
normalize the ChIP-qPCR data for potential sources of variability, including the starting chromatin amount 
in the chromatin extract, immunoprecipitation efficiency and the amount of DNA recovered (see “Materials 
and methods”). Using ChIP, we found that c-Jun bound to the Il33 enhancer in the FAK-WT-expressing cells 
(Fig. 4F). Furthermore, there was a significant loss of c-Jun binding in FAK-kd-expressing cells in comparison 
to FAK-WT-expressing cells (Fig. 4F). These data are consistent with FAK kinase activity regulating chromatin 
accessibility at the enhancer region upstream of the Il33 gene at the predicted c-Jun binding site.
Next, we wanted to address whether FAK kinase activity may regulate the levels of phosphorylation of c-Jun. 
Transcriptional activation of c-Jun is mediated by phosphorylation of Serine 73 by c-Jun N-terminal kinase 
(JNK)27. Treatment of FAK-WT SCC cells with the FAK kinase inhibitor VS4718 resulted in a significant loss 
S73-c-Jun phosphorylation (Supplementary Figure S4). Interestingly, there was also a significant reduction of 
total c-Jun protein levels. There was therefore a change in the amount of cellular pS73-c-Jun upon treatment 
with a FAK kinase activity inhibitor, and we conclude that FAK kinase activity contributes to the amount of 
transcriptionally active c-Jun in the SCC cells used here.
Thus, we conclude that FAK, which is classically thought to be primarily an integrin adhesion protein, can 
function in the nucleus to control chromatin accessibility at specific gene promoters/enhancers. In turn, this 
leads to FAK-dependent transcription of specific genes, an example of which is the cytokine Il33. FAK/IL-33 
downstream effectors significantly influence tumor  biology9.
Discussion
In this study, we have discovered an undescribed function of nuclear FAK as a key regulator of chromatin acces-
sibility changes and transcription factor binding. Furthermore, we have confirmed that nuclear FAK regulates 
c-Jun binding at the Il33 enhancer region via chromatin accessibility changes to control Il33 expression. As 
IL-33 is an important regulator of cytokine expression and tumor  growth8, FAK-dependent c-Jun regulation of 
IL-33 expression would be predicted to influence cancer cell biology, such as that we described  previously9. It 
is perhaps not surprising that FAK can regulate c-Jun, since cytoplasmic-localized FAK is known to transduce 
signals through pathways such as  MAPK28 and  Wnt29,30, which are known to control c-Jun expression and its 
transcriptional  activity18,31; however, what is surprising is the more direct link we have uncovered here between 
nuclear FAK function and its regulation of c-Jun transcriptional activity at the Il33 enhancer via chromatin acces-
sibility. Consistent with the links between nuclear FAK and c-Jun activity being more common, nuclear FAK is 
reported to regulate the expression of Jun (which encodes c-Jun) in response to ‘stretch’ in cardiac myocytes by 
binding to, and enhancing, the transcriptional activity of  MEF232.
Focal adhesion proteins other than FAK have been detected in the nucleus, such as  Lpp33 and Hic-534, which 
are believed to function as transcription factor co-regulators33,35. Furthermore, the focal adhesion protein pax-
illin can also translocate to the  nucleus36, where it contributes to  proliferation37, and we believe that there are 
other integrin-linked adhesion proteins capable of translocating to the nucleus and functioning at the nuclear 
membrane or inside the  nucleus38. Relevant to the work we present here, a number of consensus adhesome com-
ponents containing LIM (Lin11–Isl1–Mec3) domains have been directly linked to the regulation of chromatin 
accessibility and dynamics. For example, Hic-5 can inhibit the binding of the glucocorticoid receptor to the 
chromatin remodelers chromodomain-helicase DNA binding protein 9 (also known as ATP-dependent helicase 
CHD9) and brahma (also known as ATP-dependent helicase SMARCA2), resulting in a closed chromatin con-
formation and transcriptional repression of a subset of glucocorticoid receptor target  genes35,39. Also, paxillin 
can regulate proliferation-associated gene expression by controlling promoter–enhancer looping via nuclear 
interactions with the cohesin and mediator  complex37. Taken together, these reports suggest that focal adhesion 
Figure 4.  c-Jun regulates IL-33 expression by binding to Il33 enhancer regions. (A,B) FAK-WT SCC cells were 
transfected with a non-targeting control (NTC) or Jun SMARTpool (SP) siRNA. Jun (A) and Il33 (B) qRT-
PCRs were carried out using Jun and Il33 primers, respectively. Fold gene expression changes were calculated 
by normalizing cycle threshold (Ct) values to GAPDH and FAK-WT NTC Ct values. (C) FAK-WT-expressing 
cells were transfected with NTC or individual Jun siRNAs, and whole cell lysates were subjected to SDS-PAGE 
analysis. Blots were stained with IL-33, c-Jun and GAPDH antibodies (left panel). IL-33 protein expression 
was quantified by densitometry using ImageJ/Fiji software (v2.1.0, imagej.net/Fiji) and values normalized to 
GAPDH densitometry values (right panel). c-Jun knockdown was checked on a separate blot. Full length blots 
are reported in Supplementary Fig. S3. (D) FAK-WT cells were transfected with NTC or Jun SMARTpool 
siRNA. qRT-PCR was carried out using Cxcl10 primers. (E) Schematic detailing the locations of ChIP primers 
upstream of the Il33 gene. (F) Primers were designed to capture the c-Jun motif upstream of the Il33 gene (c-Jun 
motif primer) and in the upstream region of the Il33 gene to control for background binding (background 
primer). Pull-down efficiency was calculated using the % input method (see “Materials and methods”). (G) FAK 
(blue) translocates to the nucleus and binds to transcriptional regulators (i.e. chromatin accessibility regulators 
and co-activators) (TR, green). At the level of the Il33 gene, TRs potentially scaffold FAK to chromatin-
modifying complexes to regulate chromatin accessibility changes at the Il33 gene enhancer, allowing binding of 
the AP-1 complex containing c-Jun (yellow). AP-1 binding stimulates IL-33 expression, which suppresses the 
anti-tumor immune response and promotes tumor growth, as shown  previously9. Images from Servier Medical 
Art (http://smart .servi er.com/) were adapted under terms of a Creative Commons Attribution 3.0 Unported 
License: CC BY 3.0 Servier. Data are mean ± SEM. n = 3 biological replicates (A–D) or 5 biological replicates (F). 
ns not significant; *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001 by unpaired two-tailed t test (A,B,D), one-
way ANOVA (C) or t test with Welch’s correction (F).
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proteins in the nucleus are capable of scaffolding chromatin remodeling complexes to regulate chromatin struc-
ture and gene expression changes.
An unanswered question is the mechanism by which FAK controls chromatin accessibility at regulated genes. 
In this regard, our previous nuclear interactome proteomics revealed that FAK can interact with proteins known 
to regulate chromatin  accessibility7. These include the Smarcc2 and Actl6a components of the BRG1/BRM-
associated factor (BAF)  complex7, which have been shown to be recruited to target gene enhancers by AP-1 to 
regulate chromatin  accessibility40. IL-33 is required for the chromatin recruitment of the Wdr82 component of 
the chromatin-modifying protein serine/threonine phosphatase (PTW/PP1 phosphatase)  complex9,41. IL-33 
binds to the Brd4 (bromodomain-containing protein 4) transcriptional  coactivator9, which is known to recruit 
the BAF complex to target  genes42. The nuclear FAK binding protein Sp-1 also interacts with the BAF complex 
to facilitate its recruitment to specific  promoters43. Therefore, there is abundant evidence of connections between 
FAK or FAK binding proteins (i.e. FAK–Sp-1, FAK–IL-33) and FAK-regulated transcription factors (e.g. AP-1) 
to chromatin accessibility factors, such as the BAF complex and PTW/PP1 phosphatase complex. It is likely that 
FAK, and proteins to which it binds, scaffold chromatin remodeling proteins at target genes, such as Il33 as we 
describe here, in order to determine the state of chromatin accessibility, the binding of transcription factors like 
AP-1 and transcription (Fig. 4G). Once IL-33 expression is activated, FAK and IL-33 bind and co-operate to 
regulate target gene expression (e.g. Cxcl10) in the nucleus by interacting with a network of chromatin modifiers 
and transcriptional  regulators9.
One limitation to this study is that our ATAC-seq analysis was only performed in one species. However, we 
note that the HOMER  tool15 uses motifs from a number of sources, including human and mouse. Indeed, many 
of the transcription factor motifs are highly conserved between related organisms, with DNA binding profiles 
for human and mouse transcription factors being almost identical. This high homology makes the information 
about transcription factors specifically interchangeable between  organisms15. Furthermore, many transcription 
factors have high protein sequence homology between species. For example, mouse c-Jun is 96% homologous 
to its human  counterpart44. In addition, the information used to predicted the c-Jun/CRE motif upstream of 
the Il33 enhancer originated from a human ChIP-seq dataset [K562-cJun-ChIP-Seq(GSE31477)]. Therefore, 
our mouse c-Jun ChIP analysis at this CRE motif has experimentally confirmed that there is homology in AP-1 
binding motifs between mouse and human. As such, we believe that the data presented in this manuscript are 
also applicable to human cell lines.
In summary, we have discovered a completely new paradigm for how FAK may regulate transcription in the 
nucleus, i.e. as a critical regulator of chromatin accessibility changes at biologically important target genes, such 
as Il33 we show here. Translocation of FAK to the nucleus, where it can bind to factors that control chromatin 
accessibility, can therefore communicate extracellular cues to the gene transcription machinery in the nucleus 
by this route.
Materials and methods
FAK SCC cell line generation. Generation of the FAK SCC cell model has been described  previously10. 
Briefly, K14CreER FAKflox/flox in FVB mice were subjected to the dimethylbenz[a]anthracene/12-O-tetrade-
canoylphorbol 13-acetate two-stage cutaneous chemical carcinogenesis protocol. FAK deletion was induced by 
culturing excised SCC cells in 4-hydroxytamoxifen. FAK-WT, FAK kinase-deficient (FAK-kd; K454R) or FAK 
nuclear localization sequence-mutated (FAK-nls; R177A, R178A, R190A, R191A, R216A, R218A) constructs 
were stably expressed in a FAK−/− clone using standard retroviral induction protocols (for further details,  see7,10). 
Cells expressing FAK-WT and FAK mutant constructs were selected using 0.25 mg/ml hygromycin.
Tissue culture. FAK−/− and FAK-WT-, FAK-nls- and FAK-kd-expressing SCC cell lines were cultured at 
37  °C, 5%  CO2, in 1 × Glasgow minimum essential medium (GMEM) supplemented with 10% fetal bovine 
serum, 1% MEM non-essential amino acids, 1% sodium pyruvate, 1% l-glutamine and 1% MEM vitamins (all 
from Sigma-Aldrich).
ATAC‑seq. ATAC-seq samples were prepared similarly to described  previously45. The specific ATAC-seq 
protocol used in this study has been previously  reported46. ATAC-seq data were aligned to the Mus musculus ref-
erence genome mm10 using the bcbio ATAC-seq  pipeline47. Accessible regions (i.e. ATAC-seq peaks) were called 
from the BAM files using the MACS2  algorithm48 with the following parameters: -B -broad -q 0.05 -nomodel 
-shift -100 -extsize 200 -g 1.87e9. Differentially accessible regions between the FAK-WT-expressing cells and the 
FAK−/−, FAK-nls-expressing and FAK-kd-expressing cells were identified by differential peak calling using the R/
Bioconductor package  DiffBind14, where significantly different peaks were defined as those with a false discov-
ery rate (FDR) of below or equal to 0.05. Motif-enrichment analysis was performed using  HOMER15 following 
default parameters. ATAC-seq peaks were assigned to genes using  ChIPseeker17 with the following parameters: 
tssRegion = c(− 500, 2000), annoDb = "org.Mm.eg.db", TxDb = TxDb.Mmusculus.UCSC.mm10.knownGene.
Set analysis of ATAC-seq data in Figs. 1B and 2B was performed using VENNy  software49.
siRNA transfection. FAK-WT SCC cells were transfected with either siGenome Jun SMARTpool (cat. no. 
D-001210-02-05; Dharmacon), siGenome Jun siRNA #1, siGenome Jun siRNA #2 (cat. no. MQ-043776-01-
0002; Dharmacon) or non-targeting control siRNA #2 (cat. no. D-001210-02-05; Dharmacon) diluted in 500 μl 
Opti-MEM Reduced Serum Medium with GlutaMAX (Gibco) to a final concentration of 33 μM. Transfections 
were carried out using Lipofectamine RNAiMAX transfection reagent (Invitrogen) following manufacturer’s 
instructions. Cells were incubated in transfection mixes for 48 h before harvesting for RNA extraction or whole 
cell lysate preparation.
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Chromatin immunoprecipitation (ChIP)‑qPCR. The ChIP-qPCR experiments were performed as 
described  previously50,51. FAK-WT- and FAK-kd-expressing cells (4 × 106) were plated on 10-cm dishes (Corn-
ing) and then, the following day, were formaldehyde crosslinked and fractionated as described  in50. Sonication 
was carried out using a BioRupter (Diagenode) at high power for 10 min (30-s on/off cycles) to yield DNA 
fragments of 1000–200 bp in size. The samples were then centrifuged at 13,000 rpm for 15 min at 4 °C. The 
supernatant was collected and 50 µl reserved for an input sample. For immunoprecipitations, a protein A and 
protein G Dynabead mixture (1:1) (both from Invitrogen) was added to sonicated lysate along with 0.48 µg of 
c-Jun antibody (cat. no. 9165; Cell Signaling Technology) or equal amount of rabbit IgG (cat. no. 2729; Cell 
Signaling Technology). Immunoprecipitations were incubated at 4 °C overnight with rotation, prior to washing 
with 1 × RIPA 150 mM NaCl (50 mM Tris–HCl [pH 8], 150 mM NaCl, 1 mM EDTA, 0.2% SDS, 0.2% sodium 
deoxycholate, 1% Triton X-100), 1 × RIPA 500 mM NaCl (50 mM Tris–HCl [pH 8], 500 mM NaCl, 1 mM EDTA, 
0.2% SDS, 0.2% sodium deoxycholate, 1% Triton X-100) and twice with cold Tris–EDTA (TE) buffer [10 mM 
Tris–HCl (pH 8), 1 mM EDTA (pH 8)], before resuspension in 200 µl of ChIP direct elution buffer (10 mM 
Tris–HCl [pH 8], 300 mM NaCl, 5 mM EDTA [pH 8], 0.5% SDS). Input samples were made up to 200 μl with 1 × 
RIPA 150 mM NaCl and 0.4% SDS. Both the input and immunoprecipitation samples were incubated for 5 h at 
65 °C. The following day, the input and immunoprecipitation eluates samples were treated with 2 µl of RNaseA/
T1 (Ambion) for 30 min at 37 °C and 5 µl of 10 mg/ml proteinase K (Ambion) for 1 h at 55 °C. The DNA was 
then purified using the QIAquick PCR purification kit (Qiagen) following manufacturer’s instructions.
ChIP and input DNA were amplified using the following primers: c-Jun motif/Il33 enhancer, F: ACC CTG 
GAG TGT TCT TTG CA and R: TGC CTT CTG AAG CTT ACT CGA; negative control region, F: ATG TGT GCT GTG 
TGT ATG CC and R: ACA TTA AGG GCA GGA GAC GT. ChIP-qPCR analysis was performed using SYBR Green 
master mix (Thermo Scientific) following manufacturer’s instructions. The following cycling conditions were 
used: 98 °C for 10 s, 30 × (98 °C for 10 s, 60 °C for 1 min and 72 °C for 4 min) and 72 °C for 5 min. The % input 
method was used for c-Jun ChIP data normalization, whereby the cycle threshold (Ct) values of the ChIP samples 
are divided by the Ct values of the input sample (starting amount of chromatin used for the ChIP). The input 
sample Ct value was first adjusted using the following equation: adjusted input = Ct of input sample − log2(dilution 
factor). Then the % input was calculated for the CRE c-Jun ChIP and the background control region upstream of 
the Il33 gene using the following calculation: 100 × (PCR amplification factor)(adjusted input − PCR Ct value(c-Jun ChIP)). Then 
the % input of the CRE motif was subtracted from the % input of the background control region to determine 
the amount of enrichment of c-Jun binding to the CRE motif over the background control region.
RT‑qPCR. RNA extraction was performed using an RNeasy Mini kit (Qiagen) following manufacturer’s 
instructions. cDNA synthesis was performed using the SuperScript First-strand Synthesis System (Invitrogen) 
following the manufacturer’s random hexamers protocol. qRT-PCR analysis was performed using SYBR Green 
master mix (Thermo Scientific) following manufacturer’s instructions. The following cycling conditions were 
used: 98 °C for 10 s, 30 × (98 °C for 10 s, 60 °C for 1 min and 72 °C for 4 min) and 72 °C for 5 min. Primers 
used were as follows: Il33, F: GGA TCC GAT TTT CGA GAC TTA AAC AT and R: GCG GCC GCA TGA GAC CTA 
GAA TGA AGT; Cxcl10, F: CCC ACG TGT TGA GAT CAT TG and R: CAC TGG GTA AAG GGG AGT GA; GAPDH, 
F: CTG CAG TAC TGT GGG GAG GT and R: CAA AGG CGG AGT TAC CAG AG. Jun was amplified using pre-
designed primers from Qiagen (cat no. QT00296541).
Cell lysis and immunoblotting. Cell lysis and immunoblotting was performed exactly as described 
 previously9. Antibodies used in this study were as follows: IL-33 (cat. no. BAF3626; R&D Systems), c-Jun (cat. no. 
9165; Cell Signaling Technology), Phospho-FAK (Tyr397) (cat. no. 3283; Cell Signaling Technology), Phospho-
c-Jun (Ser73) (cat. no. 3270; Cell Signaling Technology), GAPDH (cat. no. 5174; Cell Signaling Technology).
FAK kinase inhibitor treatment. FAK-WT SCC cells were treated with 250 nM VS4718 (Selleckchem) 
for 24 h, prior to cell lysis and immunoblotting.
RNA‑seq. RNA was extracted from FAK-WT, FAK−/− and FAK-kd SCC cells using an RNeasy kit (Qiagen) 
following manufacturer’s instructions. To verify sample purity, the samples were run on a 2100 Bioanalyzer using 
the Bioanalyzer RNA 6000 pico assay (both Agilent). Samples that achieved an RNA integrity number (RIN) 
of 8 or above were considered suitable purity for sequencing. Samples were prepared for sequencing using the 
TruSeq RNA Library Prep Kit v2 (low-sample protocol) (Illumina) and paired-end sequenced using a HiSeq 
4000 platform (Illumina) at BGI.
Transcript abundance was determined using the pseudoalignment software  kallisto52 on the mouse transcrip-
tome database acquired using the kallisto index, implementing default parameters. Quality control was performed 
on the kallisto output using MultiQC software (https ://githu b.com/ewels /Multi QC). Transcript abundance was 
summarized to gene level and imported into the differential expression analysis R package  DESeq253 using the 
R package  tximport54. Genes which had zero read counts were removed prior to differential expression analysis.
Differential expression analysis was performed using DESeq2 using default parameters, where FAK-WT 
vs FAK−/− and FAK-WT vs FAK-kd SCC cell line gene read counts were compared. The Wald test was used for 
hypothesis testing in DESeq2, and all P-values were corrected for multiple testing using the Benjamini–Hoch-
berg method. Transcripts that acquired a Benjamini–Hochberg corrected P-value of 0.05 or below and a 
 log2-transformed fold change in expression of ≥ 1 or ≤ – 1 were considered significantly different between the 
cell lines. RNA-seq results from FAK-WT and FAK−/− cells were previously  analyzed38; RNA-seq data from all 
cell lines (Supplementary Data S2) were deposited in the NCBI Gene Expression Omnibus (GEO)55 (GEO series 
accession number: GSE147670).
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Protein domain‑enrichment analysis. Protein domain-enrichment analysis was performed for SMART 
domains using  DAVID56,57. All terms that acquired a Benjamini–Hochberg corrected P-value of below 0.05 were 
considered statistically significant.
Network analysis. Network analysis was performed using Ingenuity Pathway Analysis (QIAGEN Inc., 
https ://www.qiage nbioi nform atics .com/produ cts/ingen uityp athwa y-analy sis). The following parameters were 
used for network construction: database sources (Ingenuity expert information, protein–protein interaction 
database, BioGrid, IntAct), direct interaction, experimentally observed, protein–protein and functional interac-
tions, mammalian interactions only. All networks were exported into  Cytoscape58, and the NetworkAnalyzer 
 plugin59 was used to visualize the most connected nodes in the networks before applying yFiles layout algorithms 
(yWorks).
Statistical analysis. Statistical analysis was performed using Prism 8 (GraphPad Software). All P-values 
below 0.05 were considered statistically significant.
Data availability
The RNA-seq and ATAC-seq data have been deposited in the Gene Expression Omnibus and are accessible 
through GEO series accession identifiers GSE147670 and GSE161022, respectively.
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